The acquisition will expand AbbVie's exploration of in vivo CAR-T therapy, an ambitious approach that could sidestep some of the difficulties presented by current cell treatments.
|
The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review standards.
|
Q&A
Industry veteran Catherine Owen Adams expects external innovation will be key to getting the brain-focused drug developer to “the next level.”
|
Smarter data. Stronger evidence. Better outcomes. See how top life sciences firms use RWD/RWE to lead.
|
Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray into pivotal testing.
|
The biotech, which agreed to be bought by Supernus after clinical and commercial struggles, plans to lay off 338 employees by late August.
|
Recommended For You
Improve your recommendations: click here to update your profile.
Deep Dive
The success of Vertex's opioid alternative Journavx could aid a group of biotechs that aim to take a similar path with NaV1.8 and NaV1.7 inhibitors.
|
|
GSK transformed drug development by investing in claims data early and revealing critical treatment dynamics. Learn their approach to securing budget, maximizing ROI and de-risking programs in this webinar.
|
|
From Our Library
Webinar - on demand
Custom content for MMIT
|
Trendline
Supported by Premier Inc
|
View all resources
| 
